1. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR, Tortora G (2000) Antitumour effect and potentiation of cytotoxic drug activity in human cancer cells by ZD1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6: 2053–2063
2. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Jean-Yves Douillard, Nishiwaki Y, Vansteenkiste JF, Kudo S, Averbuch S, Macleod A, Feyereislova A, José Baselga (2002) Final results from a phase II trial of ZD 1839 (Iressa) for patients with advanced non-small cell lung cancer (IDEAL 1). Proc Am Soc Clin Oncol 21: 298a (abstract 1188)
3. Giaccone G, Johnson DH, Manegold C, Scagliotti GV, Rosell R, Wolf M, Renne P, Ochs J, Averbuch S, Fandi A (2002) A phase III clinical trial of ZD 1839 (Iressa) in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (INTACT 1). Ann Oncol 13: 2 abstract 40 (vocal)
4. Johnson DH, Herbst R, Giaccone G, Schiller J, Natale RB, Miller V, Wolf M, Helton A, Averbuch S, Grous J (2002) ZD 1839 (Iressa) in combination with paclitaxel & carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC): results from a phase III clinical trial (INTACT 2). Ann Oncol 13: 127 abstract 4680 (vocal).
5. Kris MG, Herbst R, Rischin D, LoRusso P, Baselga J, Hammond L, Feyereislova A, Ochs J, Averbuch S (2000) Objective regressions in non-small cell lung cancer patients treated in phase I trials of ZD1839 (‘Iressa’), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR). Lung Cancer 29: 72 (Suppl 1, poster 233).